头颈癌根治性放疗后立体定向放疗作为计划加量的系统综述
本系统综述检索Medline、EMBASE和Cochrane Library(建库至2021年1月),纳入9项研究、454例接受根治性放疗的多部位头颈癌患者,评估常规放疗后以立体定向放疗(SBRT)作为计划加量的疗效与毒性。3年局部控制率中位数92%(90%-98%),总生存率中位数80%(75%-91%),报告7例(1.5%)治疗相关5级毒性。作者认为尽管局部控制和总生存可接受,但存在严重治疗相关晚期毒性,SBRT加量应仅限研究性场景使用。
要点
- 9项研究共454例头颈癌患者接受常规放疗后SBRT计划加量。
- 3年局部控制率中位数92%(90%-98%),总生存率中位数80%(75%-91%)。
- 报告7例(1.5%)治疗相关5级毒性及严重晚期毒性,作者认为SBRT加量应仅限研究性场景。
核心结论
- 尽管局部控制率和总生存率可接受,但存在严重治疗相关晚期毒性,SBRT加量应仅在研究性场景中使用,直至获得更多数据。
研究设计与样本
- 系统综述,检索Medline、EMBASE和Cochrane Library数据库,检索时间自建库至2021年1月,纳入9项研究、454例接受根治性放疗的多部位头颈癌患者。
主要发现
- 3年局部控制率中位数92%(90%-98%)。
- 3年总生存率中位数80%(75%-91%)。
- 报告7例(1.5%)治疗相关5级毒性。
- 存在严重治疗相关晚期毒性。
临床怎么用
- 作者认为,SBRT加量应仅在研究性场景中使用,直至获得更多数据。
局限性
- 存在严重治疗相关晚期毒性;作者认为需更多数据后才可在研究性场景外使用SBRT加量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Management of locoregionally advanced head and neck cancers (HNCs) remains a challenge. Some groups have attempted to use stereotactic radiotherapy (SBRT) to deliver "boost" treatment following conventional radiotherapy to improve local control (LC) and overall survival (OS), while aiming for acceptable toxicities. Medline, EMBASE, and Cochrane Library databases were queried for SBRT as curative-intent planned boost in HNC after conventional radiotherapy. Individual studies were reviewed from inception until January 2021, extracting patient, treatment, and outcome data. Nine studies met inclusion criteria, representing 454 unique patients treated with curative intent across multiple head and neck sites with conventional radiotherapy. At 3 years, median LC was 92% (90%-98%), and median OS was 80% (75%-91%). Seven treatment-related grade 5 toxicities (1.5%) were reported. Despite acceptable LC and OS rates, there were severe treatment-related late toxicities. As such, SBRT boost should only be used in investigational settings until more data is available.
引用
- Kim MS, Malik NH, Chen H, et al. Stereotactic radiotherapy as planned boost after definitive radiotherapy for head and neck cancers: Systematic review. Head Neck. 2021. PMID: 34927313. doi:10.1002/hed.26948
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。